Expressing the sense of the House of Representatives that the United States should not waive intellectual property rights relating to COVID-19 vaccines or treatments.

Bill 117 H.Res. 484, titled "Expressing the sense of the House of Representatives that the United States should not waive intellectual property rights relating to COVID-19 vaccines or treatments," is a resolution introduced in the US Congress. The purpose of this resolution is to convey the opinion of the House of Representatives that the United States should not support the waiver of intellectual property rights related to COVID-19 vaccines or treatments.

The resolution emphasizes the importance of protecting intellectual property rights as a means to incentivize innovation and ensure that pharmaceutical companies have the resources and motivation to develop new vaccines and treatments. It argues that waiving these rights could undermine the ability of companies to recoup their investments and could potentially discourage future research and development efforts.

The resolution also highlights the role of intellectual property rights in promoting competition and ensuring quality control in the pharmaceutical industry. It suggests that allowing the waiver of these rights could lead to a decrease in the quality and safety of vaccines and treatments, as well as potentially hinder the ability of companies to quickly respond to future pandemics. Overall, Bill 117 H.Res. 484 expresses the belief of the House of Representatives that protecting intellectual property rights related to COVID-19 vaccines and treatments is crucial for promoting innovation, ensuring quality, and maintaining the incentives necessary for continued research and development in the pharmaceutical industry.